Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.35 |
| ▸ | WEE1 | P30291 | 3/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | GRK6 | P43250 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295621 | 0.87 | CYP1A2 (0.33) | CHEK1WEE1TLR8MAPTCNR2 | |
| SCHEMBL2300170 | 0.85 | TLR8 (0.38) | CHEK1WEE1TLR8CNR2 | |
| SCHEMBL2297735 | 0.85 | TLR8 (0.39) | CHEK1WEE1TLR8CNR2HTT | |
| SCHEMBL2300163 | 0.83 | SMN1; SMN2 (0.32) | TP53MAPTSMN1; SMN2 | |
| SCHEMBL2300121 | 0.82 | TGFBR1 (0.36) | TLR8TP53APLNR | |
| SCHEMBL4114788 | 0.82 | CASP1 (0.34) | CHEK1WEE1TLR8TP53MAPT | |
| SCHEMBL2299695 | 0.82 | PSEN1 (0.36) | CHEK1WEE1TLR8MAPTCNR2 | |
| SCHEMBL2301220 | 0.82 | AGTR1 (0.42) | — | |
| SCHEMBL2298814 | 0.82 | KDM4E (0.42) | TLR8TP53MAPTCNR2TSHR | |
| SCHEMBL2301194 | 0.81 | PPARG (0.40) | CHEK1WEE1TLR8MAPTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312975-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | YANG ZHE (US) | 2011-12-22 | — | — | US | claimed |
| EP-2244711-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Incorporated (US) | 2010-11-03 | — | — | EP | claimed |
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED | 2009-10-08 | — | — | US | claimed |
| WO-2009099594-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2009-08-13 | — | — | WO | claimed |
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TNNC1, TNNI3, TNNT2 | CHEK1 337/4885WEE1 3750/4885TLR8 4623/4885 |
| US-20110312975-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | TNNC1, TNNI3, TNNT2 | CHEK1 259/4885WEE1 3898/4885TLR8 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.